Skip to content

Safety and efficacy of LipidUp-PE in the management of premature ejaculation.

Safety and efficacy of LibidUp-PE on premature ejaculation: A randomized placebo controlled double blind crossover study

Status
Active, not recruiting
Phases
Phase 3Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/10/037471
Enrollment
60
Registered
2021-10-22
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N528- Other male erectile dysfunction

Interventions

Intervention1: LipidUp-PE: Daily 2 sachets mix in 200ml of water Control Intervention1: Placebo: Daily 2 sachets mix in 200ml of water

Sponsors

MMC Pharmaceuticals Ltd
Lead Sponsor
SRM Medical College Hospital and Research Centre
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Subjects meeting with diagnostic criteria for Premature Ejaculation (PE score greater than or equal to 11). Subjects must be in a stable, monogamous, sexual relationship with the same partner for at least 6 months and plan to maintain this relationship for the duration of the trial. Subjects with intravaginal ejaculatory latency time (IELT) of � 2 minutes. Subjects who are willing to sign informed consent for participation in the study.

Exclusion criteria

Exclusion criteria: ïâ??§Subjects with genital anatomical deformities including but not limited to penile deformities. ïâ??§Use of any investigational drug within the past month ïâ??§Subjects with major psychiatric illness or previous suicidal attempts. ïâ??§Subjects with history of epilepsy ïâ??§Subjects with alcohol abuse, dependence, smoking addiction, and on any other drugs which can interfere with ejaculation can be excluded ïâ??§Subjects with significant and uncontrolled hematological /metabolic/ endocrinologial/ respiratory/ cardiovascular/ neurological/psychiatric/liver/ gastrointestinal/kidney diseases or other significant pathological conditions which is judged by Investigator may affect subject participation in the study

Design outcomes

Primary

MeasureTime frame
To evaluate the effect of LipidUp-PE on Serotonin (5-hydroxytryptamine, 5-HT) in subjects with premature ejaculation.Timepoint: First response rate can be measured at 1st week from the day of the therapy for 4 weeks

Secondary

MeasureTime frame
To assess the effect of LipidUp-PE on IntravaginalEjaculatory Latency Time (IELT) and Premature Ejaculation Diagnostic Tool (PEDT) scores in subjects with premature ejaculation.Timepoint: At Initial and after 12th Week

Countries

India

Contacts

Public ContactDr RC Satish Kumar

SRM Institute of Science and Technology

srinivasan.thimmaraju@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026